# Targeting Donor Regulatory Dendritic Cells During Normothermic Ex Vivo Liver Perfusion to Overcome Rejection after Liver Transplant

> **NIH NIH K08** · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $149,952

## Abstract

ABSTRACT
 This proposal presents a five-year research career development program focused on targeting donor liver-
resident cells with regulatory properties to decrease rejection after transplantation. I am an Assistant Professor
of Surgery at the University of Wisconsin-Madison, with previous research and clinical experience in transplant
immunology and transplant surgery involving normothermic ex vivo machine perfusion (NEVLP), whereby an
organ is housed under physiologic conditions. The present project will advance the field of transplant
immunology by using NEVLP technology to modify the immune cells within the liver prior to transplantation. I
have assembled an outstanding mentorship team of investigators with expertise in transplant immunology,
dendritic cell biology, and extracellular vesicle biology. The proposed training will guide and enhance my
development in core competencies, including transplant immunology, communication, biostatistics, and ethical
research design that will enable me to transition to research independence as a surgeon-scientist dedicated to
reducing organ rejection in the field of transplant surgery.
 Liver transplantation is the only treatment option for patients with end-stage liver disease; however,
rejection of the transplant can decrease liver and patient survival. In addition, patients still require lifelong use
of anti-rejection medications that suppress the immune system. Modification of the donor liver, and the immune
cells within it, has the potential to promote acceptance of the liver and minimize the need for anti-rejection
drugs. Advances in an innovative technique called normothermic ex vivo liver perfusion (NEVLP) offer a unique
opportunity to benefit significantly the 25% of liver transplant recipients that develop acute rejection, as well as
many more transplant recipients who would benefit from using fewer anti-rejection drugs. Recent studies have
demonstrated the importance of regulatory dendritic cells (DCregs) for prolonging transplant survival. My
central hypothesis is that expansion of the number of liver-resident DCregs during NEVLP will promote a
regulatory environment for the organ after transplant. Using a rat model of NEVLP and liver transplantation that
my research group has optimized, I expect NEVLP to expand DCregs potently, leading to an increase in
immune checkpoint molecule expression and production of anti-inflammatory extracellular vesicles and
cytokines that can reduce immune-mediated rejection. This innovative approach of expanding graft-resident
DCregs to decrease rejection could be used in deceased donor liver transplantation as well as translated to
other types of solid organ transplants. To achieve these objectives, I propose the following scientific aims:
1) Determine the dominant regulatory function of liver-resident DCregs after NEVLP, and 2) Measure the
impact of expanded liver-resident DCregs generated by combination cytokine therapy during NEVLP on liver
graft rejectio...

## Key facts

- **NIH application ID:** 10837050
- **Project number:** 5K08AI155816-04
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** David Peter Al-Adra
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $149,952
- **Award type:** 5
- **Project period:** 2021-06-07 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10837050

## Citation

> US National Institutes of Health, RePORTER application 10837050, Targeting Donor Regulatory Dendritic Cells During Normothermic Ex Vivo Liver Perfusion to Overcome Rejection after Liver Transplant (5K08AI155816-04). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10837050. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*